MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Edoxaban

Search medical newsFind research, conditions and clinical updates
  • Home
  • Edoxaban
Rethinking Rhythm Control for Secondary Stroke Prevention: Insights from the STABLED Randomized Clinical Trial
Posted inClinical Updates Neurology news

Rethinking Rhythm Control for Secondary Stroke Prevention: Insights from the STABLED Randomized Clinical Trial

Posted by By MedXY 03/06/2026
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
Read More
Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial
Posted inCardiology Neurology news

Catheter Ablation and Edoxaban for Secondary Stroke Prevention: Critical Analysis of the STABLED Randomized Trial

Posted by By MedXY 03/02/2026
The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a recent history of ischemic stroke.
Read More
Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation
Posted inCardiology news

Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation

Posted by By MedXY 01/03/2026
A hierarchical win ratio analysis of the NOAH-AFNET 6 trial confirms that edoxaban does not provide a net clinical benefit over no anticoagulation in patients with device-detected atrial fibrillation, primarily due to the balance between low stroke rates and significant bleeding risks.
Read More
Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial
Posted inCardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

Posted by By MedXY 08/17/2025
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.
Read More
Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial
Posted inCardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

Posted by By MedXY 08/17/2025
The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • The Global Physical Literacy (GloPL) Action Framework: Consensus Process and Practical Recommendations
  • Aligning Rehabilitation Priorities to Enhance Home and Work Functioning in Low Back Pain: Insights from a Stakeholder-Driven Group Concept Mapping Study
  • Enhancing Diagnostic Confidence in Endodontics: Patient Perspectives on Cone-Beam Computed Tomography and Radiation Awareness
  • Empirical Tuberculosis Treatment in Infants Living with HIV Hospitalised with Severe Pneumonia in Africa (EMPIRICAL): A Comprehensive Review of a Multicentre Randomised Controlled Trial
  • Elevated Mental Health Diagnosis Prevalence Among Children With Complex and Chronic Medical Conditions: Implications for Screening and Equity
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top